MLN518 in Combination With Standard Induction Chemo. for Treatment of Patients With Newly Diagnosed Acute Myelogenous Leukemia

NCT00274248 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

INDUSTRY

Sponsor class

Conditions

Acute Myelogenous Leukemia

Interventions

DRUG: MLN518

Sponsor

Millennium Pharmaceuticals, Inc.